Clinical Studies Search

Protocol Summary


Protocol No.
PSCI-20-066
Prinicipal Investigator
Ma, Patrick
Phase
Phase II
Age Group
Adult
Scope
National
Secondary Protocol No.
CX-839-014
Title
A Phase II Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) CX-839-014
Objective
The study objectives and endpoints were designed to determine the benefit of telaglenastat in combination with pembrolizumab plus chemotherapy compared with placebo in combination with pembrolizumab plus chemotherapy as first-line treatment of patients with metastatic KEAP1- or NRF2-mutated nonsquamous Stage IV NSCLC.
Applicable Disease Sites
Lung
Status
Open
Participating Institutions
Hershey Medical Center